Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 6/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16503765 | 0.90 | EPHX1 (0.39) | IDO1CES2TACR1EPHX1DAO | |
| SCHEMBL28560207 | 0.90 | EPHX1 (0.39) | IDO1CES2TACR1EPHX1DAO | |
| SCHEMBL45135 | 0.90 | RXRA (0.43) | IDO1TACR1EPHX1SLC6A4CAPN1 | |
| SCHEMBL25138788 | 0.89 | TACR1 (0.46) | IDO1CES2TACR1EPHX1DAO | |
| SCHEMBL28484226 | 0.84 | CES2 (0.48) | IDO1CES2TACR1DAOSLC6A4 | |
| SCHEMBL28545725 | 0.83 | P2RX1 (0.40) | EPHX1LMNAAURKA | |
| SCHEMBL1015795 | 0.82 | LMNA (0.54) | CES2TACR1LMNARXRARXRB | |
| SCHEMBL30645023 | 0.82 | TAAR1 (0.62) | IDO1EPHX1AURKA | |
| SCHEMBL185922 | 0.82 | TAAR1 (0.62) | IDO1EPHX1AURKA | |
| SCHEMBL2387771 | 0.81 | RXRA (0.50) | CAPN1LMNARXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377064-A1 | ORVEPITANT FOR THE TREATMENT OF CHRONIC COUGH | NeRRe Therapeutics Limited (GB) | 2018-09-26 | — | — | EP | claimed |
| WO-2017118584-A1 | ORVEPITANT FOR THE TREATMENT OF CHRONIC COUGH | NERRE THERAPEUTICS LIMITED (GB) | 2017-07-13 | — | — | WO | claimed |
| EP-2906219-A1 | NOVEL USES | NeRRe Therapeutics Limited (GB) | 2015-08-19 | — | — | EP | claimed |
| WO-2012175434-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING VESTIPITANT | GLAXO GROUP LIMITED (GB) | 2012-12-27 | — | — | WO | claimed |
| US-7276509-B2 | Piperidine derivatives and their use as antagonists of tachykinins | GLAXO GROUP LIMITED (GB) | 2007-10-02 | — | — | US | claimed |
| US-6951861-B1 | Chemical compounds | SMITHKLINE BEECHAN CORPORATION (US) | 2005-10-04 | — | — | US | claimed |
| US-20050096313-A1 | Piperidine derivatives and their use as antagonists of tachykinins | GLAXO GROUP LIMITED (GB) | 2005-05-05 | — | — | US | claimed |
| EP-1472243-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | claimed |
| EP-1218359-B1 | PIPERAZINE COMPOUNDS AS TACHYKININS ANTAGONISTS | GLAXO GROUP LTD (GB) | 2004-07-07 | — | — | EP | claimed |
| EP-1377558-A1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | claimed |
| WO-2003066621-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | claimed |
| WO-2002081457-A1 | `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | claimed |
| US-11813248-B2 | NK-1 antagonist compositions and methods for use in treating depression | CHASE THERAPEUTICS CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023111938-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA, Alexandre (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-20220168281-A1 | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION | CHASE THERAPEUTICS CORPORATION (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220160683-A1 | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION | CHASE THERAPEUTICS CORPORATION (US) | 2022-05-26 | — | — | US | disclosed |
| WO-2003066635-A1 | PIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2002081457-A1 | `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096313-A1 | Piperidine derivatives and their use as antagonists of tachykinins | NPSR1, TACR1, OPRL1 | IDO1 764/4885CES2 1325/4885TACR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.